Abstract
Metalloprotein is a basic term for a proteins that contains a metal ion cofactor, have many functions in cells, such as enzymes, transport and storage proteins, and signal transduction proteins. The balance between MMPs and TIMPs are critical in extracellular matrix (ECM) development, morphogenesis, tissue repair and remodeling through MAPK Pathway. Excess of MMPs and TIMPs shows adverse effects, leading to aging diseases such as Alzheimer’s Disease, Cancer, Asthma, Diabetes 2 Mellitus etc. Human Protein Reference Dataset (HPRD) assessed 10 interactions for TIMP1, 5 interactions for TIMP2, 8 interactions for TIMP3 and 2 interactions for TIMP4. The data also assessed 11 interactions for MMP1 and 11 interactions for MMP2. The data from HPRD and Pathwaylinker has also predicted the interaction of Metalloproteins with aging diseases. In the present experimentation, in silico docking models predicted that Iron and Cobalt are activators for TIMPs and MMPs. These metals can serve as an important reactants with good binding affinity for TIMPs and MMPs. Except TIMP1 and TIMP2, all other TIMPs used in present experimentation have good binding affinities with Cyanocobalamin. Hence Cyanocobalamine can be used in treatment of various diseases such as D2M, Cancer, Alzheimer and Parkinson diseases in low dose for longer period, in control of MAPK pathway.
Keywords: MMP, TIMP, Metallic compounds, Protein-protein interactions, Docking, Anti-aging, Bioinformatics, Metalloproteins, ERK1/2, Pulmonary Disease
Letters in Drug Design & Discovery
Title:Protein Interaction Networks in Metallo Proteins and Docking Approaches of Metallic Compounds with TIMP and MMP in Control of MAPK Pathway
Volume: 10 Issue: 1
Author(s): Kaladhar Svgk Dowluru, Potladurthi Chandra Sai, Padmanabhuni Venkata Nageswara Rao, Amajala Krishna chaitanya, Duddukuri Govinda Rao, Vadlapudi Varahala Rao, Potladurthi Suresh, Erva Rajeswara Reddy, Sudabattula Vijaya kumar, Divyakolu Vinod Kumar and Gajjala Bhaskar Reddy
Affiliation:
Keywords: MMP, TIMP, Metallic compounds, Protein-protein interactions, Docking, Anti-aging, Bioinformatics, Metalloproteins, ERK1/2, Pulmonary Disease
Abstract: Metalloprotein is a basic term for a proteins that contains a metal ion cofactor, have many functions in cells, such as enzymes, transport and storage proteins, and signal transduction proteins. The balance between MMPs and TIMPs are critical in extracellular matrix (ECM) development, morphogenesis, tissue repair and remodeling through MAPK Pathway. Excess of MMPs and TIMPs shows adverse effects, leading to aging diseases such as Alzheimer’s Disease, Cancer, Asthma, Diabetes 2 Mellitus etc. Human Protein Reference Dataset (HPRD) assessed 10 interactions for TIMP1, 5 interactions for TIMP2, 8 interactions for TIMP3 and 2 interactions for TIMP4. The data also assessed 11 interactions for MMP1 and 11 interactions for MMP2. The data from HPRD and Pathwaylinker has also predicted the interaction of Metalloproteins with aging diseases. In the present experimentation, in silico docking models predicted that Iron and Cobalt are activators for TIMPs and MMPs. These metals can serve as an important reactants with good binding affinity for TIMPs and MMPs. Except TIMP1 and TIMP2, all other TIMPs used in present experimentation have good binding affinities with Cyanocobalamin. Hence Cyanocobalamine can be used in treatment of various diseases such as D2M, Cancer, Alzheimer and Parkinson diseases in low dose for longer period, in control of MAPK pathway.
Export Options
About this article
Cite this article as:
Svgk Dowluru Kaladhar, Chandra Sai Potladurthi, Venkata Nageswara Rao Padmanabhuni, Krishna chaitanya Amajala, Govinda Rao Duddukuri, Varahala Rao Vadlapudi, Suresh Potladurthi, Rajeswara Reddy Erva, Vijaya kumar Sudabattula, Vinod Kumar Divyakolu and Bhaskar Reddy Gajjala, Protein Interaction Networks in Metallo Proteins and Docking Approaches of Metallic Compounds with TIMP and MMP in Control of MAPK Pathway, Letters in Drug Design & Discovery 2013; 10 (1) . https://dx.doi.org/10.2174/1570180811309010049
DOI https://dx.doi.org/10.2174/1570180811309010049 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Enzymes Oxidizing the Azo Dye 1-Phenylazo-2-Naphthol (Sudan I) and their Contribution to its Genotoxicity and Carcinogenicity
Current Drug Metabolism Chronic Inflammatory Diseases: Progress and Prospect with Herbal Medicine
Current Pharmaceutical Design Extending the Clinical Horizons of Mucosal Bacterial Vaccines: Current Evidence and Future Prospects
Current Drug Targets Tumour Targeting with Systemically Administered Bacteria
Current Gene Therapy Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment
Current Medicinal Chemistry Nanoparticles Mediated Target-specific Drug Delivery in Prostate Cancer: An In-depth Review
Current Medicinal Chemistry Poxvirus-Based Vaccines for Cancer Immunotherapy: New Insights from Combined Cytokines/Co-Stimulatory Molecules Delivery and “Uncommon” Strains
Anti-Cancer Agents in Medicinal Chemistry Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents
Current Pharmaceutical Design Anticancer Mechanisms of Berberine: A Good Choice for Glioblastoma Multiforme Therapy
Current Medicinal Chemistry Prostaglandin E<sub>2</sub> Receptor 4 (EP4): A Promising Therapeutic Target for the Treatment of Cancer and Inflammatory Diseases
Current Chemical Biology LncRNAs as Architects in Cancer Biomarkers with Interface of Epitranscriptomics- Incipient Targets in Cancer Therapy
Current Cancer Drug Targets Carbonyl-Scavenging Drugs & Protection Against Carbonyl Stress-Associated Cell Injury
Mini-Reviews in Medicinal Chemistry Pharmacogenomics of COPD
Current Pharmacogenomics Exosome Limitations in the Treatment of Inflammatory Diseases
Current Pharmaceutical Design Inflammation and Cancer: In Medio Stat Nano
Current Medicinal Chemistry Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Optimal Dosing Design for Antibiotic Therapy in the Elderly: A Pharmacokinetic and Pharmacodynamic Perspective
Recent Patents on Anti-Infective Drug Discovery Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design